TY - JOUR
T1 - Heart Failure Symptom Biology in Response to Ventricular Assist Device Implantation
AU - Lee, Christopher S.
AU - Mudd, James O.
AU - Lyons, Karen S.
AU - Denfeld, Quin E.
AU - Jurgens, Corrine Y.
AU - Aouizerat, Bradley E.
AU - Gelow, Jill M.
AU - Chien, Christopher V.
AU - Aarons, Emily
AU - Grady, Kathleen L.
N1 - Funding Information:
Undergraduate Research Fellow, Boston College William F. Connell School of Nursing, Chestnut Hill, Massachusetts. Kathleen L. Grady, PhD, RN, FAHA, FAAN, FHFSA Professor, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. This project was supported by the National Institutes of Health/National Institute of Nursing Research (1R01NR013492). The research reported in this article also was supported by the National Center for Advancing Translational Sciences (UL1TR000128). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Nursing Research or the National Institutes of Health. The authors have no conflicts of interest to disclose. Correspondence Christopher S. Lee, PhD, RN, FAHA, FAAN, FHFSA, Boston College School of Nursing, 140 Commonwealth Avenue: Maloney Hall 226, Chestnut Hill, MA 02467 ([email protected]). DOI: 10.1097/JCN.0000000000000552
Publisher Copyright:
© 2019 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Background: We have a limited understanding of the biological underpinnings of symptoms in heart failure (HF), particularly in response to left ventricular assist device (LVAD) implantation. Objective: The aim of this study was to quantify the degree to which symptoms and biomarkers change in parallel from before implantation through the first 6 months after LVAD implantation in advanced HF. Methods: This was a prospective cohort study of 101 patients receiving an LVAD for the management of advanced HF. Data on symptoms (dyspnea, early and subtle symptoms [HF Somatic Perception Scale], pain severity [Brief Pain Inventory], wake disturbance [Epworth Sleepiness Scale], depression [Patient Health Questionnaire], and anxiety [Brief Symptom Inventory]) and peripheral biomarkers of myocardial stretch, systemic inflammation, and hypervolumetric mechanical stress were measured before implantation with a commercially available LVAD and again at 30, 90, and 180 days after LVAD implantation. Latent growth curve and parallel process modeling were used to describe changes in symptoms and biomarkers and the degree to which they change in parallel in response to LVAD implantation. Results: In response to LVAD implantation, changes in myocardial stretch were closely associated with changes in early and subtle physical symptoms as well as depression, and changes in hypervolumetric stress were closely associated with changes in pain severity and wake disturbances. Changes in systemic inflammation were not closely associated with changes in physical or affective symptoms in response to LVAD implantation. Conclusions: These findings provide new insights into the many ways in which symptoms and biomarkers provide concordant or discordant information about LVAD response.
AB - Background: We have a limited understanding of the biological underpinnings of symptoms in heart failure (HF), particularly in response to left ventricular assist device (LVAD) implantation. Objective: The aim of this study was to quantify the degree to which symptoms and biomarkers change in parallel from before implantation through the first 6 months after LVAD implantation in advanced HF. Methods: This was a prospective cohort study of 101 patients receiving an LVAD for the management of advanced HF. Data on symptoms (dyspnea, early and subtle symptoms [HF Somatic Perception Scale], pain severity [Brief Pain Inventory], wake disturbance [Epworth Sleepiness Scale], depression [Patient Health Questionnaire], and anxiety [Brief Symptom Inventory]) and peripheral biomarkers of myocardial stretch, systemic inflammation, and hypervolumetric mechanical stress were measured before implantation with a commercially available LVAD and again at 30, 90, and 180 days after LVAD implantation. Latent growth curve and parallel process modeling were used to describe changes in symptoms and biomarkers and the degree to which they change in parallel in response to LVAD implantation. Results: In response to LVAD implantation, changes in myocardial stretch were closely associated with changes in early and subtle physical symptoms as well as depression, and changes in hypervolumetric stress were closely associated with changes in pain severity and wake disturbances. Changes in systemic inflammation were not closely associated with changes in physical or affective symptoms in response to LVAD implantation. Conclusions: These findings provide new insights into the many ways in which symptoms and biomarkers provide concordant or discordant information about LVAD response.
KW - affective symptoms
KW - biomarkers
KW - heart failure
KW - signs and symptoms
UR - http://www.scopus.com/inward/record.url?scp=85061291898&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061291898&partnerID=8YFLogxK
U2 - 10.1097/JCN.0000000000000552
DO - 10.1097/JCN.0000000000000552
M3 - Article
C2 - 30489416
AN - SCOPUS:85061291898
SN - 0889-4655
VL - 34
SP - 174
EP - 182
JO - Journal of Cardiovascular Nursing
JF - Journal of Cardiovascular Nursing
IS - 2
ER -